Hospitals face tighter budgets. ASC competition is intensifying. And a major policy shift is reshaping how non-opioid pain therapies are paid for in the outpatient setting. The NOPAIN Act is one of the most consequential reimbursement changes for pain management stakeholders in years.
Here’s what you need to know.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ What is the NOPAIN Act and why it matters now
➜ Medicare reimbursement for non-opioid drugs: How it works
➜ Impact on hospital outpatient departments and ASCs
➜ Competitive landscape for non-opioid pain therapies
➜ How to apply NOPAIN act insights to market strategy
➜ Frequently Asked Questions about NOPAIN Act
Key Takeaways
- Effective January 1, 2025: separate Medicare Part B payment for qualifying non-opioid drugs in HOPDs and ASCs, ending cost absorption under bundled payments.
- Directly lowers the financial barrier to adoption in cost-sensitive outpatient settings.
- Biggest near-term winners: branded non-opioid injectables and long-acting local anesthetics.
- Manufacturers must coordinate FDA approval and CMS reimbursement timelines to capture early share.
- Outpatient procedure migration is accelerating, early movers gain a durable formulary advantage.
What is the NOPAIN Act and why it matters now
The NOPAIN Act was passed by the U.S. Congress to increase patient access to non-opioid pain management options. The law requires the Centers for Medicare & Medicaid Services to provide separate reimbursement for certain non-opioid drugs used in hospital outpatient departments and ambulatory surgery centers.
Before this change, many non-opioid drugs were bundled into procedure payments. That created a cost burden for facilities. When hospitals had to absorb the drug cost, adoption slowed.
In 2026, separate payment reduces that barrier. This has direct implications for utilization, formulary decisions, and competitive share shifts.
For medtech manufacturers, hospital formulary committees, and ASC administrators, this shift is a direct driver of utilization, procurement, and competitive positioning in 2026 and beyond.
Medicare reimbursement for non-opioid drugs: How it works
The biggest shift under the NOPAIN Act is separate payment under Medicare Part B for qualifying non-opioid products. This means hospitals can receive additional reimbursement instead of covering the cost within a bundled payment.
How it works:
- Products must receive CMS designation as a qualifying non-opioid treatment; FDA approval is required, and not all non-opioid agents automatically qualify.
- HOPDs are paid under OPPS; ASCs are paid under the ASC payment system — rates differ between settings.
- CMS updates payment rates annually through the OPPS final rule, so reimbursement levels for specific products may shift.
For manufacturers, this means active engagement with CMS coverage and coding is essential — passive eligibility is not guaranteed.
Impact on hospital outpatient departments and ASCs
Hospital outpatient departments and ASCs operate on tight margins. Under bundled payments, higher-cost drugs can reduce profitability per case. This often limits uptake even if clinical data is strong.
With separate reimbursement beginning in 2025, facilities can reassess their protocols. This may increase trial use of long-acting local anesthetics and injectable non-opioid agents.
Still, adoption will vary. Facilities must update billing systems, educate clinicians, and adjust purchasing contracts. Early adopters may gain marketing advantages with surgeons focused on opioid-sparing protocols.
Hospitals that prepare operationally will move faster than those waiting for clear utilization trends.
👉 Learn more in the U.S. Pain Management Device Market Report and Forecast to 2032.
Competitive landscape for non-opioid pain therapies
Established branded products with existing FDA approval benefit first. Emerging players see a window of opportunity as reimbursement barriers fall, but must still build CMS eligibility and health economic evidence.
The biggest share shifts will concentrate among premium non-opioid injectables where pricing previously suppressed adoption.
Companies combining reimbursement support, provider education, and outcomes data will secure formulary positions faster.
That first-mover advantage is real, and time-limited.
How to apply NOPAIN act insights to market strategy
Manufacturers should treat 2026 as a positioning year. First, confirm reimbursement status and educate sales teams on billing pathways. Second, build economic value messaging tailored to outpatient administrators.
Market access teams should monitor CMS rule updates closely. Even small adjustments in payment classifications can affect utilization rates. Competitive intelligence should track which products gain early ASC contracts.
Investors and strategists should also watch procedure migration trends. As more cases shift to outpatient settings, reimbursement alignment becomes more important.
Understanding where adoption barriers remain will separate short-term policy excitement from sustainable growth.
Frequently Asked Questions about NOPAIN Act
What does NOPAIN stand for?
Non-Opioids Prevent Addiction In the Nation. Enacted as part of the Consolidated Appropriations Act, 2023; separate payment took effect January 1, 2025.
Which drugs qualify for separate payment?
Not all non-opioid pain drugs qualify automatically. Products must have FDA approval and receive CMS designation as a qualifying non-opioid pain treatment. Eligibility details are published through the annual OPPS final rule.
When did NOPAIN Act reimbursement begin?
January 1, 2025, under OPPS for hospital outpatient departments and under the ASC payment system for ambulatory surgery centers.
How does it affect ASCs specifically?
ASCs previously absorbed non-opioid drug costs within fixed bundled payments. Separate reimbursement removes that margin compression, enabling formulary decisions based on clinical and operational value rather than cost-absorption.
Does it apply to commercial insurance?
The mandate is specific to Medicare. Commercial payers vary, though Medicare decisions often influence commercial coverage over time — timelines are payer-dependent and not guaranteed.
What is the difference between HOPD and ASC payment under NOPAIN?
Both settings receive separate reimbursement for qualifying products, but payment rates differ — HOPDs under OPPS, ASCs under the ASC payment system. Manufacturers should model reimbursement for each setting separately.
NOPAIN Act Summary
The NOPAIN Act is a reimbursement reform designed to expand access to non-opioid pain management in outpatient settings. By requiring separate Medicare payment, it reduces a major financial barrier that previously slowed adoption.
In 2026, the law creates opportunity. It also increases competition. Companies that align regulatory, reimbursement, and commercial strategy will capture early gains.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
